mRNA—From COVID-19 Treatment to Cancer Immunotherapy
Author:
Open Access
- 22 January 2023
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 11 (2) , 308
Abstract
This review provides an overview covering mRNA from its use in the COVID-19 pandemic to cancer immunotherapy, starting from the selection of appropriate antigens, tumor-associated and tumor-specific antigens, neoantigens, the basics of optimizing the mRNA molecule in terms of stability, efficacy, and tolerability, choosing the best formulation and the optimal route of administration, to summarizing current clinical trials of mRNA vaccines in tumor therapy.Keywords
This publication has 232 references indexed in Scilit:
- Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**Angewandte Chemie International Edition, 2012
- Increased Erythropoiesis in Mice Injected With Submicrogram Quantities of Pseudouridine-containing mRNA Encoding ErythropoietinMolecular Therapy, 2012
- Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNANucleic Acids Research, 2011
- HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+T lymphocytesProceedings of the National Academy of Sciences, 2011
- Global quantification of mammalian gene expression controlNature, 2011
- Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated PatientsMolecular Therapy, 2011
- Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells with Synthetic Modified mRNACell Stem Cell, 2010
- RIG-I Detects Viral Genomic RNA during Negative-Strand RNA Virus InfectionCell, 2010
- Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological StabilityMolecular Therapy, 2008
- A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trialVaccine, 2008